CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research
- 18 June 2021
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 10 (6), 1245-1267
- https://doi.org/10.1021/acssynbio.1c00107
Abstract
Over the past decades, significant progress has been made in targeted cancer therapy. In precision oncology, molecular profiling of cancer patients enables the use of targeted cancer therapeutics. However, current diagnostic methods for molecular analysis of cancer are costly and require sophisticated equipment. Moreover, targeted cancer therapeutics such as monoclonal antibodies and small-molecule drugs may cause off-target effects and they are available for only a minority of cancer driver proteins. Therefore, there is still a need for versatile, efficient, and precise tools for cancer diagnostics and targeted cancer treatment. In recent years, the CRISPR-based genome and transcriptome engineering toolbox has expanded rapidly. Particularly, the RNA-targeting CRISPR-Cas13 system has unique biochemical properties, making Cas13 a promising tool for cancer diagnosis, therapy, and research. Cas13-based diagnostic methods allow early detection and monitoring of cancer markers from liquid biopsy samples without the need for complex instrumentation. In addition, Cas13 can be used for targeted cancer therapy through degrading and manipulating cancer-associated transcripts with high efficiency and specificity. Moreover, Cas13-mediated programmable RNA manipulation tools offer invaluable opportunities for cancer research, identification of drug-resistance mechanisms, and discovery of novel therapeutic targets. Here, we review and discuss the current use and potential applications of the CRISPR-Cas13 system in cancer diagnosis, therapy, and research. Thus, researchers will gain a deep understanding of CRISPR-Cas13 technologies, which have the potential to be used as next-generation cancer diagnostics and therapeutics.This publication has 231 references indexed in Scilit:
- High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cellsNature Biotechnology, 2013
- Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinomaNature Medicine, 2013
- Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic CancerClinical Chemistry, 2012
- Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer DrugsThe Oncologist, 2011
- Antitumorigenic potential of STAT3 alternative splicing modulationProceedings of the National Academy of Sciences of the United States of America, 2011
- A serum circulating miRNA diagnostic test to identify asymptomatic high‐risk individuals with early stage lung cancerEMBO Molecular Medicine, 2011
- Stand-alone self-powered integrated microfluidic blood analysis system (SIMBAS)Lab on a Chip, 2011
- CRISPR Provides Acquired Resistance Against Viruses in ProkaryotesScience, 2007
- Evidence for reassociation of RNA-binding proteins after cell lysis: Implications for the interpretation of immunoprecipitation analysesRNA, 2004
- Expression profiling reveals off-target gene regulation by RNAiNature Biotechnology, 2003